指南与共识艾滋病与性传播感染

国家采用全员治疗指南对ART前CD4检测及ART后病毒载量监测的影响:回归断点分析

Effects of National Adoption of Treat-All Guidelines on Pre-Antiretroviral Therapy (ART) CD4 Testing and Viral Load Monitoring After ART initiation: A Regression Discontinuity Analysis.
指南 / 共识 · Clin Infect Dis · 2021-01-01

结果显示,中低收入国家成人ART前CD4检测立即下降8.9个百分点,而高收入国家成人略有上升,青少年和儿童无显著变化;ART后病毒载量监测在中低收入国家成人中立即增加2.9个百分点,且趋势显著上升。结论认为全员治疗政策改善了病毒载量监测,但加剧了ART前CD4监测不足。

要点

  • 中低收入国家成人ART前CD4检测率从57.0%降至48.1%,下降8.9个百分点。
  • 高收入国家成人ART前CD4检测率从90.1%升至91.7%,上升1.6个百分点。
  • 中低收入国家成人ART后病毒载量监测率从58.2%升至61.1%,上升2.9个百分点。

核心结论

  • 全员治疗政策后中低收入国家ART后病毒载量监测改善,但ART前CD4监测加速且不平等地恶化,可能影响晚期HIV患者的照护结局。

研究设计与样本

  • 分析成人(≥20岁)、青少年(10-19岁)和儿童(0-9岁)在低/中低收入国家(L/LMICs)和高/中高收入国家(H/UMICs)的ART前12个月内CD4检测和ART后6个月病毒载量监测。

主要发现

  • L/LMICs成人ART前CD4检测立即下降,从57.0%至48.1%(-8.9个百分点;95% CI:-11.0,-6.8),且下降趋势在政策后加速。
  • H/UMICs成人ART前CD4检测小幅上升,从90.1%至91.7%(+1.6个百分点;95% CI:0.2,3.0),青少年和儿童无变化。
  • L/LMICs成人ART后病毒载量监测立即增加,从58.2%至61.1%(+2.9个百分点;95% CI:0.5,5.4),青少年和儿童无显著变化;政策后病毒载量监测趋势显著上升。

临床怎么用

  • 在推广全员治疗的同时,应关注并维持ART前CD4检测,尤其在中低收入国家成人中,以识别晚期HIV患者并优化照护。
  • 加强ART后病毒载量监测的趋势改善,但需注意青少年和儿童监测未显著变化,应针对这些人群强化监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Health Organization's Treat-All guidance recommends CD4 testing before initiating antiretroviral therapy (ART), and routine viral load (VL) monitoring (over CD4 monitoring) for patients on ART. METHODS: We used regression discontinuity analyses to estimate changes in CD4 testing and VL monitoring among 547 837 ART-naive patients enrolling in human immunodeficiency virus (HIV) care during 2006-2018 at 225 clinics in 26 countries where Treat-All policies were adopted. We examined CD4 testing within 12 months before and VL monitoring 6 months after ART initiation among adults (≥20 years), adolescents (10-19 years), and children (0-9 years) in low/lower-middle-income countries (L/LMICs) and high/upper-middle-income countries (H/UMICs). RESULTS: Treat-All adoption led to an immediate decrease in pre-ART CD4 testing among adults in L/LMICs, from 57.0% to 48.1% (-8.9 percentage points [pp]; 95% CI: -11.0, -6.8), and a small increase in H/UMICs, from 90.1% to 91.7% (+1.6pp; 95% CI: 0.2, 3.0), with no changes among adolescents or children; decreases in pre-ART CD4 testing accelerated after Treat-All adoption in L/LMICs. In L/LMICs, VL monitoring after ART initiation was low among all patients in L/LMICs before Treat-All; while there was no immediate change at Treat-All adoption, VL monitoring trends significantly increased afterwards. VL monitoring increased among adults immediately after Treat-All adoption, from 58.2% to 61.1% (+2.9pp; 95% CI: 0.5, 5.4), with no significant changes among adolescents/children. CONCLUSIONS: While on-ART VL monitoring has improved in L/LMICs, Treat-All adoption has accelerated and disparately worsened suboptimal pre-ART CD4 monitoring, which may compromise care outcomes for individuals with advanced HIV.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Brazier E, Tymejczyk O, Zaniewski E, et al. Effects of National Adoption of Treat-All Guidelines on Pre-Antiretroviral Therapy (ART) CD4 Testing and Viral Load Monitoring After ART initiation: A Regression Discontinuity Analysis. Clin Infect Dis. 2021. PMID: 33693517. doi:10.1093/cid/ciab222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。